Seaport Therapeutics CEO Discusses IPO Success on 400th Episode of Biotech Podcast
Seaport Therapeutics CEO Daphne Zohar joins the 400th episode of 'The Readout LOUD' to discuss the biotech's successful IPO. The episode also covers t...
Xeber.world
biotech news
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
FDA Revisits Rare Cancer Drug Approval After Unexpected Rejection Sparks Controversy
The FDA is reconsidering its decision to reject a treatment for a rare cancer after an unexpected rejection. Meanwhile, experts question the Trump adm...
Clene's Gold-Based ALS Treatment: Why Experts Remain Skeptical About CNM-Au8
Clene’s experimental ALS treatment, CNM-Au8, is a gold nanocrystal suspension in water. Despite its claims, experts question its efficacy as a cure, c...
Axsome Secures FDA Approval for Alzheimer’s Agitation Treatment, Marking Major Milestone in Neurotherapeutics
Axsome Therapeutics has received FDA approval for its Alzheimer’s agitation drug, marking a significant advancement in neurotherapeutic treatments. Th...
Breakthrough Five-Mechanism Obesity Drug Shows Promise in Mice, NIH Funding Hits Record Low
A next-generation obesity drug combining five mechanisms has demonstrated superlative effectiveness in mice, potentially surpassing GLP-1 drugs. Meanw...
Akeso’s Lung Cancer Drug Takes Center Stage at ASCO Plenary: What Survival Data Reveals
Akeso and Summit Therapeutics’ experimental lung cancer drug ivonescimab is the focus of Wall Street speculation ahead of ASCO’s annual meeting. The u...
Medicare Postpones Obesity Drug Coverage Pilot Amid Biotech Updates on RevMed, Roche, and Kyverna CAR-T Therapy
Medicare has delayed a pilot program to cover obesity drugs for seniors, reversing a key healthcare initiative from the Trump administration. This com...